Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

MUMBAI, India and NAPLES, Fla., June 3, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the United States…

Lupin and Natco get FDA approval for Eribulin Mesylate Injection

MUMBAI, India and NAPLES, Fla. — Lupin Ltd. and alliance partner Natco Pharma Ltd. have received approval from the U.S. Food and Drug Administration for Natco’s abbreviated new drug application for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials.The product is the bioequivalent of Eisai’s Halaven Injection and is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two che…

Lupin, Natco receive US FDA approval for Eribulin Mesylate Injection

Lupin and its alliance partner Natco Pharma have received approval from the United States Food and Drug Administration (US FDA) for Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. According to the companies, Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent of the reference listed drug (RLD), Halaven Injection of Eisai. Eribulin Mesy…